Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200525 | 0.90 | L3MBTL1 (0.41) | ALDH1A1L3MBTL1MAPTNPSR1GLA | |
| SCHEMBL182827 | 0.90 | MAPT (0.46) | ALDH1A1L3MBTL1MAPTNPSR1GLA | |
| SCHEMBL159256 | 0.90 | KDM4E (0.42) | ALDH1A1MAPTKDM4EGAAMAPK1 | |
| SCHEMBL21268380 | 0.89 | L3MBTL1 (0.42) | ALDH1A1NQO1L3MBTL1MAPTNPSR1 | |
| SCHEMBL2457659 | 0.87 | L3MBTL1 (0.43) | ALDH1A1L3MBTL1MAPTNPSR1GLA | |
| SCHEMBL2459479 | 0.87 | L3MBTL1 (0.42) | ALDH1A1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL11022484 | 0.86 | L3MBTL1 (0.37) | ALDH1A1L3MBTL1MAPTNPSR1GLA | |
| SCHEMBL2889568 | 0.86 | RIPK1 (0.40) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL3463523 | 0.85 | ADRA2A (0.33) | ALDH1A1NQO1L3MBTL1MAPTNPSR1 | |
| SCHEMBL3034721 | 0.85 | ALDH1A1 (0.32) | ALDH1A1NQO1L3MBTL1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 973 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170847-B | Novel method for preparing drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2022-02-18 | — | — | CN | claimed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | claimed |
| EP-3038621-B1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RES INSTITUTE (US) | 2020-12-02 | — | — | EP | claimed |
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | claimed |
| EP-3681888-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2020-07-22 | — | — | EP | claimed |
| CN-111212839-A | Pyrazolopyrimidinone compounds and uses thereof | 艾杜罗生物科技公司 | 2020-05-29 | — | — | CN | claimed |
| CN-111170847-A | Novel method for preparing drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2020-05-19 | — | — | CN | claimed |
| CN-109796351-A | A kind of novel preparation method of drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2019-05-24 | — | — | CN | claimed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | claimed |
| WO-2019055750-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-03-21 | — | — | WO | claimed |
| WO-1998039323-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 1998-09-11 | — | — | WO | claimed |
| WO-1998024763-A2 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AS PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-06-11 | — | — | WO | claimed |
| US-5703098-A | INHIBITORS OF CYTOKINES INCLUDING TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| EP-0797437-A1 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a) | CELGENE CORPORATION (US) | 1997-10-01 | — | — | EP | claimed |
| WO-1996020705-A1 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a) | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | claimed |
| EP-0632102-A1 | Mass dyeing of synthetic material | BAYER AG (DE) | 1995-01-04 | — | — | EP | claimed |
| US-5231105-A | Ethylamine derivatives and antihypertensives containing the same | AJINOMOTO CO., INC. (JP) | 1993-07-27 | — | — | US | claimed |
| US-4716168-A | STIMULANTS OF IMMUNE RESPONSE | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-12-29 | — | — | US | claimed |
| EP-0187705-A2 | Imidazo(4,5-f)quinolines useful as immunomodulating agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-07-16 | — | — | EP | claimed |
| US-4153718-A | Anti-inflammatory compounds | BEECHAM GROUP LIMITED (GB) | 1979-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | ALDH1A1 1246/4885NQO1 51/4885L3MBTL1 4818/4885 |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | ALDH1A1 1413/4885NQO1 2074/4885L3MBTL1 4015/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | ALDH1A1 1246/4885NQO1 51/4885L3MBTL1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.